Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with invasive triple negative breast cancer (a specific type of breast cancer that lacks certain hormone and protein receptors), confirmed by a tissue sample, where the tumour is at least 15mm in size, with any lymph node status.
- People aged 18 years or older.
- People whose cancer has been confirmed as triple negative, meaning the tumour tests negative for oestrogen receptors, progesterone receptors, and a protein called HER2, based on standard laboratory guidelines.
- People who have not previously received any systemic (whole-body) treatment for their triple negative breast cancer.
- People who are not currently receiving any other cancer treatment (bone-strengthening medications called bisphosphonates may still be continued).
- People who are generally well enough to carry out light daily activities, with little to no limitation from their illness (confirm with trial site).
- People whose blood, liver, and kidney function results fall within acceptable ranges as determined by the trial team.
- People who are not pregnant, confirmed by a blood or urine test taken within 8 days before starting the study medication, and who agree to use highly effective contraception during treatment and for at least 90 days after the last dose.
- People who are able to swallow oral (tablet or capsule) medication.
- People who are able to understand the study requirements and have signed a consent form agreeing to take part.
Who may not be able to join:
- People whose treating doctor considers them suitable for treatment given before surgery (neoadjuvant treatment).
- People who have received any breast cancer treatment within 14 days before registering for the trial.
- People who are unable to follow the study procedures as required.
- People who have other significant medical conditions — such as psychiatric illness, infections, neurological conditions, or abnormal test results — that could interfere with the planned treatment or their ability to participate.
- People who are pregnant or currently breastfeeding.
- People who have another active cancer that requires treatment (non-invasive cancers or early-stage cancers confined to one area may not automatically exclude someone — confirm with trial site).
- People who are known to be HIV positive.
- People with known active Hepatitis B or Hepatitis C infection.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Barbro K Linderholm, MD, PhD, Sahlgrenska University Hospital
Phone: +46706045422
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To determine the proportion of patients that convert to ER expressing breast cancer
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.